1 Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
2 John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
Brain. 2016 Aug;139(Pt 8):2154-63. doi: 10.1093/brain/aww133. Epub 2016 Jun 3.
Limb girdle muscular dystrophy type 2A is the most common limb girdle muscular dystrophy form worldwide. Although strict recessive inheritance is assumed, patients carrying a single mutation in the calpain 3 gene (CAPN3) are reported. Such findings are commonly attributed to incomplete mutation screening. In this investigation, we report 37 individuals (age range: 21-85 years, 21 females and 16 males) from 10 families in whom only one mutation in CAPN3 could be identified; a 21-bp, in-frame deletion (c.643_663del21). This mutation co-segregated with evidence of muscle disease and autosomal dominant transmission in several generations. Evidence of muscle disease was indicated by muscle pain, muscle weakness and wasting, significant fat replacement of muscles on imaging, myopathic changes on muscle biopsy and loss of calpain 3 protein on western blotting. Thirty-one of 34 patients had elevated creatine kinase or myoglobin. Muscle weakness was generally milder than observed in limb girdle muscular dystrophy type 2A, but affected the same muscle groups (proximal leg, lumbar paraspinal and medial gastrocnemius muscles). In some cases, the weakness was severely disabling. The 21-bp deletion did not affect mRNA maturation. Calpain 3 expression in muscle, assessed by western blot, was below 15% of normal levels in the nine mutation carriers in whom this could be tested. Haplotype analysis in four families from three different countries suggests that the 21-bp deletion is a founder mutation. This study provides strong evidence that heterozygosity for the c.643_663del21 deletion in CAPN3 results in a dominantly inherited muscle disease. The normal expression of mutated mRNA and the severe loss of calpain 3 on western blotting, suggest a dominant negative effect with a loss-of-function mechanism affecting the calpain 3 homodimer. This renders patients deficient in calpain 3 as in limb girdle muscular dystrophy type 2A, albeit in a milder form in most cases. Based on findings in 10 families, our study indicates that a dominantly inherited pattern of calpainopathy exists, and should be considered in the diagnostic work-up and genetic counselling of patients with calpainopathy and single-allele aberrations in CAPN3.
肢带型肌营养不良 2A 是全世界最常见的肢带型肌营养不良形式。尽管假定为严格的隐性遗传,但已报道存在携带钙蛋白酶 3 基因 (CAPN3) 单一突变的患者。这些发现通常归因于不完全的突变筛查。在这项研究中,我们报告了 10 个家庭的 37 名个体(年龄范围:21-85 岁,21 名女性和 16 名男性),他们仅在 CAPN3 中发现了一个突变;一个 21 个碱基对的框内缺失(c.643_663del21)。该突变与几代人肌肉疾病的证据和常染色体显性遗传共分离。肌肉疾病的证据表明肌肉疼痛、肌肉无力和消瘦、影像学上肌肉的显著脂肪替代、肌肉活检上肌病改变和西方印迹法上钙蛋白酶 3 蛋白的缺失。34 名患者中有 31 名肌酸激酶或肌红蛋白升高。肌肉无力通常比肢带型肌营养不良 2A 观察到的更轻,但影响相同的肌肉群(小腿、腰椎旁和内侧腓肠肌)。在某些情况下,虚弱严重致残。21 个碱基对的缺失不影响 mRNA 成熟。通过 Western blot 评估肌肉中的钙蛋白酶 3 表达,在 9 名可检测到突变的突变携带者中,其表达低于正常水平的 15%。来自三个不同国家的四个家庭的单体型分析表明,21 个碱基对的缺失是一个创始突变。这项研究提供了强有力的证据,表明 CAPN3 中的 c.643_663del21 缺失杂合导致显性遗传的肌肉疾病。Western blot 上正常表达的突变 mRNA 和钙蛋白酶 3 的严重丢失表明,一种显性负效应,其功能丧失机制影响钙蛋白酶 3 同源二聚体。这使得患者缺乏钙蛋白酶 3,就像肢带型肌营养不良 2A 一样,但在大多数情况下,其形式更为温和。基于 10 个家庭的研究结果,我们的研究表明存在一种显性遗传的钙蛋白酶病模式,应在钙蛋白酶病和 CAPN3 中单个等位基因异常患者的诊断评估和遗传咨询中考虑。